Clinical trial
Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer
NCT00002967 · NSABP Foundation Inc, Other · Completed
Key facts
| NCT number | NCT00002967 |
|---|---|
| Title | Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer |
| Official title | A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 PA LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Patients With Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate |
| Start date | May 1, 1997 |
| Completion | Mar 1, 2006 |
| First posted | Sep 3, 2004 |
| Last update posted | Jun 21, 2013 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: